TScan Therapeutics (TCRX) Assets (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly Assets of $202.0 million for Q1 2026, down 39.29% year-over-year from $332.7 million in Q1 2025, and down 11.71% quarter-over-quarter from $228.8 million in Q4 2025.
TScan Therapeutics (TCRX) Assets (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Assets for 7 consecutive years, with $202.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets fell 39.29% year-over-year to $202.0 million; the TTM figure through Mar 2026 stood at $202.0 million (down 39.29% YoY), while the FY2025 annual figure was $228.8 million, down 38.35% from the prior year.
- Assets slipped to $202.0 million in Q1 2026 per TCRX's latest filing, from $228.8 million in the prior quarter.
- Across five years, Assets topped out at $374.9 million in Q2 2024 and bottomed at $152.4 million in Q2 2022.
- Historically, Assets has averaged $258.7 million across 5 years, with a median of $262.2 million in 2025.
- Annual changes were most pronounced in 2023 — Assets surged 107.93% — and 2026, when it sank 39.29%.
- TScan Therapeutics' Assets stood at $199.1 million in 2022, then soared by 36.7% to $272.1 million in 2023, then surged by 36.37% to $371.1 million in 2024, then plunged by 38.35% to $228.8 million in 2025, then declined by 11.71% to $202.0 million in 2026.
- Business Quant data shows TCRX's Assets at $202.0 million in Q1 2026, $228.8 million in Q4 2025, and $262.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - | 171.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 171.45 Mn |
| Mar 31, 2026 | 201.99 Mn |
| Dec 31, 2025 | 228.79 Mn |
| Sep 30, 2025 | 262.23 Mn |
| Jun 30, 2025 | 298.56 Mn |
| Mar 31, 2025 | 332.71 Mn |
| Dec 31, 2024 | 371.12 Mn |
| Sep 30, 2024 | 348.03 Mn |
| Jun 30, 2024 | 374.87 Mn |
| Mar 31, 2024 | 240.83 Mn |
| Dec 31, 2023 | 272.15 Mn |
| Sep 30, 2023 | 291.38 Mn |
| Jun 30, 2023 | 316.92 Mn |
| Mar 31, 2023 | 173.58 Mn |
| Dec 31, 2022 | 199.09 Mn |
| Sep 30, 2022 | 165.45 Mn |
| Jun 30, 2022 | 152.42 Mn |
| Mar 31, 2022 | 168.20 Mn |
| Dec 31, 2021 | 188.11 Mn |
| Sep 30, 2021 | 204.89 Mn |